Progress is being made in the search for a simple test for Alzheimer disease.

Yet another trial on risks and benefits of widespread PSA screening. Dr Kenny Lin puts it in perspective.

Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade.

A trial using MABp1, an antibody targeting interleukin 1 alpha, showed some benefit for patients with advanced colorectal cancer, but Dr Kerr thinks the clinical endpoint used was a 'little soft.'

At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.

Some think it's time to change how we talk about DCIS and to consider de-escalation of therapy. Drs Kathy Miller and Shelley Hwang discuss these hot topics and the COMET study at SABCS 2017.

Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.

Dr Lundberg discussed the American Society for Clinical Pathology's list of 20 lab tests you should carefully consider before ordering.

Dr JoAnn Manson comments on a recent study revealing that gestational diabetes is like a window into a woman's future risk for cardiovascular disease and type 2 diabetes.

Oncologists fail to recommend HPV vaccination to young cancer survivors, even though it is a safe and effective cancer prevention strategy.

Drs Gayatri Acharya, Michael Ackerman, and Peter Noseworthy discuss the importance of investigating sudden deaths in light of new research showing that many presumed sudden cardiac deaths are not cardiac in origin.

Dr Eric Topol speaks with science journalist Carl Zimmer about where he gets his ideas, what his genome looks like, and how he got a tapeworm named after him.

Dr Lundberg shares a possible aid for metabolizing alcohol.

Dr Califf talks about his new role at Verily and how data mining and data sharing could reduce disparities in care and improve patient outcomes.

Eric Topol gets the backstory from Beth Stevens on the amazing discoveries being made about the role of the immune system in neurologic diseases.

Dr Markman encourages review of recently reported possible effect of ovarian cancer antineoplastic agents in breast cancer patients with rare BRCA mutational signatures.

Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.

Dr Eric Topol interviews CRISPR scientist Feng Zhang about his journey from China to the gene editing labs of America.

Without a gold standard for myriad parameters, precision oncology is imprecise, at best, argues Dr Lundberg.

The just-released Testosterone Trials provide more information on screening for or treating low T. Should family physicians intervene in older men?

Dr Alan Jacobs reports on the first functional evidence of gene variants with implications for the pathology of ADHD

Dr Maurie Markman explains that sharing genetic data with study participants encourages greater clinical trial involvement.

Dr Chodak reviews a new algorithm intended to simplify PSA testing. But is it ready for prime time?

Use of molecular diagnostics in cancer can be tricky, but Dr Lundberg says the pathologist can ask important questions to help guide the process.